Practice management in the era of anti-VEGF therapy (Part I)

Article

Identifying the bottlenecks that are preventing effective management of neovascular AMD.

Recent Videos
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
At EURETINA 2024, Martin S. Zinkernagel, MD, PhD, on the future of real-world AI use
Related Content
A digital map of the world, overlaid on top of a photo of a person writing with a pen in a notebook. Image credit: ©Pixels Hunter – stock.adobe.com

Arctic Vision partners with Santen Pharmaceutical Co., Ltd. to commercialise ARVN001 in China

Sydney M Crago
November 22nd 2024
Article

ARVN001 is indicated for the treatment of uveitic macular oedema and certain other ophthalmic indications

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A European Union delegate signs a document while an EU flag is visible on the desk. Image credit: ©pressmaster – stock.adobe.com

CHMP issues positive opinion for marketing authorisation of aflibercept biosimilar FYB203 (Formycon)

Sydney M Crago
November 19th 2024
Article

The positive opinion marks a key regulatory step towards the approval of FYB203, which will go by the trade names AHZANTIVE and Baiama in the European Union

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A phone and a computer with the NHS website pulled up. The webpage on the phone says "NHS Services." Image credit: ©Timon – stock.adobe.com

NHS introduces OCT programme to reduce annual hospital visits for patients with diabetes

Hattie Hayes
November 18th 2024
Article

Optical coherence tomography will be in all eye care services by October 2025

An eye with digitally-rendered transparent DNA strands in front of it. Image credit: ©kittyfly – stock.adobe.com

US FDA clears investigational new drug application for CRISPR/Cas13 RNA-editing therapy

Sydney M Crago
November 12th 2024
Article

HG202, by HuidaGene Therapeutics, is formulated for clinical use in treating neovascular age-related macular degeneration

© 2024 MJH Life Sciences

All rights reserved.